Previous 10 | Next 10 |
Previously Announced Execution of Definitive Agreement to Acquire SenlangBio SenlangBio Generated Revenue of USD $1.2 Million for the Three Months Ended March 31, 2021 and Projects $5 Million to $7 Million in Revenue for the Full Year 2021 USD $30 Million of Committed Capi...
NEW YORK, NY / ACCESSWIRE / June 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) concerning potential violations of the federal securities laws and/or breaches of fid...
Avalon Globocare President & CEO Dr. David Jin and CFO Luisa Ingargiola - The Investor Forum at the World Stem Cell Summit. Each presentation features a formal corporate overview, followed by a Q & A session moderated by a Noble Capital Markets equity research representative. Read Mor...
Featuring Avalon GloboCare (AVCO), Caladrius Biosciences (CLBS), Celularity, ImmCelz / Creative Medical Technology Holdings (CELZ), ExoProTher, GID BIO, HealthLynked (HLYK), Longeveron (LGVN), Mesoblast (MESO) - Presented by Channelchek and Noble Capital Markets Read More >>
On the conclusion of the 2021 Russell indexes annual reconstitution, the following notable financial and real-estate companies will join the Russell 3000 Index, effective June 28 after market opens.Financial institutions set to join the Russell 3000 Index include: Finance Of America Companies...
Avalon GloboCare (AVCO) has entered into a definitive agreement to acquire PRC limited liability company Hebei Senlang Biotechnology (“SenlangBio”).SenlangBio is currently the largest cell therapy company in Northern China in terms of bio-manufacturing s...
FREEHOLD, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced that it will be presenting at the Noble Capital Markets Investor Forum during ...
Investor Forum at the World Stem Cell Summit - June 17, 2021 - presented by Channelchek - Featuring Avalon GloboCare, Caladrius Biosciences, CellZ, Celularity, ExoProTher, GID BIO, Longeveron, Medicinal Cells, Inc., Mesoblast Read More >>
FREEHOLD, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announces that the company’s President and Chief Executive Officer, David Jin, M....
Recent advances in stem cell technologies, armed with the ability to generate almost any tissue-specific cell types of the body in a dish, human pluripotent stem cells (hPSCs) have drastically moved therapeutic research forward in unprecedented ways. Stem cell-derived cells are increasingly re...
News, Short Squeeze, Breakout and More Instantly...
Avalon GloboCare Corp. Company Name:
AVCO Stock Symbol:
NASDAQ Market:
Company to Begin Trading under New Symbol “ALBT” on November 10, 2022 Symbol Change Better Reflects Avalon’s New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon...
Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a ...
Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ: AVCO) , a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Ch...